Reuters
01 Oct 2026, 12:13 UTC · 4d ago
Foghorn to cut 40% of workforce after scrapping Lilly-partnered cancer drug
Impact · against what's priced in
The news is a significant negative catalyst for Foghorn Therapeutics due to pipeline failure and workforce cuts, while it is immaterial for Eli Lilly. LLY's current valuation is driven by GLP-1 dominance and scale, making the failure of a single early-stage cancer partner drug a negligible event.
- LLY+0.00
Doesn't touch the price's assumptions
- The price assumes
The next-generation pipeline, specifically retatrutide's potential
The price is driven by GLP-1 growth and retatrutide; the failure of an early-stage partnered cancer drug does not impact the core revenue drivers or the specific pipeline assumptions listed in the reconstruction.
What LLY's price assumes · Sep 10
Top 1 mover · tap to explore
